Blood-based biomarkers for Down syndrome and Alzheimer's disease: A systematic review (Q92467879)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31389185%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

review article

1 reference

title

Blood-based biomarkers for Down syndrome and Alzheimer's disease: A systematic review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31389185%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

1 reference

1 reference

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31389185%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31389185%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

publication date

1 July 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31389185%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

number of pages

1 reference

Developmental Neurobiology

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31389185%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31389185%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31389185%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

page(s)

699-710

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31389185%20AND%20SRC:MED&resulttype=core&format=json

The Test for Severe Impairment: An Instrument for the Assessment of Patients with Severe Cognitive Dysfunction

29 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Executive dysfunction and its association with personality and behaviour changes in the development of Alzheimer's disease in adults with Down syndrome and mild to moderate learning disabilities

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Plasma amyloid beta protein 1-42 levels in fetuses with Down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Congenital heart disease and Down syndrome: various aspects of a confirmed association

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Plasma N-Glycome Signature of Down Syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Increased Soluble APPα, Abeta 1-42, and Anti-Abeta 1-42 Antibodies in Plasma From Down Syndrome Patients

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP.

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

https://api.crossref.org/works/10.1002%2FDNEU.22714

1 reference

7 January 2021

Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Plasma antioxidant enzymes and lipoperoxidation status in children with Down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Plasma Amyloid-β as a Function of Age, Level of Intellectual Disability, and Presence of Dementia in Down Syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Amyloid beta concentrations in older people with Down syndrome and dementia.

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Increased levels of plasma total tau in adult Down syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Dementia in Down syndrome: unique insights for Alzheimer disease research

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Down Syndrome Preleukemia and Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Plasma amyloid beta protein 1-42 levels are increased in old Down Syndrome but not in young Down Syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Plasma Amyloid Beta 1-42 and DNA Methylation Pattern Predict Accelerated Aging in Young Subjects with Down Syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

A blood screening test for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer's Disease.

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Molecular mapping of Alzheimer-type dementia in Down's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Current estimate of Down Syndrome population prevalence in the United States

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Critical role of the D21S55 region on chromosome 21 in the pathogenesis of Down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Chromosome 21q21 sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Clinical Assessment of Cognitive Decline in Adults with Down Syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Change in plasma Aß peptides and onset of dementia in adults with Down syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Validating the Cognitive Scale for Down Syndrome (CS-DS) to Detect Longitudinal Cognitive Decline in Adults With Down Syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Amyloid beta protein species in cerebrospinal fluid and in brain from patients with Down's syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

CSF tau and Abeta42 levels in patients with Down's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Genetic variability at the amyloid-beta precursor protein locus may contribute to the risk of late-onset Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FDNEU.22714

7 January 2021

Identifiers

DOI

10.1002/DNEU.22714

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31389185%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31389185%20AND%20SRC:MED&resulttype=core&format=json